Hallucinogen persisting perception disorder: A literature review and three case reports

References

• INCB. Report of the International Narcotics Control Board for 2018 (E/INCB/20148/1). https://www.incb.org/documents/Publications/AnnualReports/AR2018/Annual_Report/Annual_Report_2018_E_.pdf
   Google Scholar
• Ivanets NN, Anokhina IP, Vinnikova MA. Narcology: National guidelines. Moscow: GEOTAR-Media, 2008:445–476 (in Russian).
   Google Scholar
• UNODC. Understanding the synthetic drug market: The NPS factor. Global SMART Update. 2018;19. p.7. https://www.unodc.org/documents/scientific/Global_Smart_Update_2018_Vol.19.pdf. Accessed 02 Oct. 2019.
   Google Scholar
• Diagnostic and statistical manual of mental disorders. 5th ed. 2. Mental disorders – classification. 3. Mental disorders – diagnosis. WM 15:481–590, 809–916. https://www.psychiatry.org/psychiatrists/practice/dsm (date of the appeal: 14.05.2019). Accessed 02 Oct. 2019.
   Google Scholar
• Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, di Giannantonio M, Lerner AG. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8:47. doi:10.3390/brainsci8030047.
   Web of Science ®Google Scholar
• Espiard ML, Lecardeur L, Abadie P, Halbecq I, Dollfus S. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Eur Psychiatr. 2005;20:458–460. doi:10.1016/j.eurpsy.2005.04.008.
   PubMed Web of Science ®Google Scholar
• Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. 2003;107:131–146.
   PubMed Web of Science ®Google Scholar
• Halpern JH, Pope HG. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 2003;69:109–119. doi:10.1016/s0376-8716(02)00306-x.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Rudinski D, Bor O, Goodman C. Flashbacks and HPPD: a clinical-oriented concise review. Israel J Psychiatr Relat Sci. 2014;51:296–302.
   PubMed Web of Science ®Google Scholar
• Litjens RP, Brunt TM, Alderliefste GJ, Westerink RH. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol. 2014;24:1309–1323. doi:10.1016/j.euroneuro.2014.05.008.
   PubMed Web of Science ®Google Scholar
• Vroegop MP, Dongen RT, Vantroyen B, Kramers C. [Ketamine as a party drug]. Ned Tijdschr Geneeskd. 2007;151:2039–2042.
   PubMedGoogle Scholar
• Ziaee V, Akbari Hamed E, Hoshmand A, Amini H, Kebriaeizadeh A, Saman K. Side effects of dextromethorphan abuse, a case series. Addict Behav. 2005;30:1607–1613. doi:10.1016/j.addbeh.2005.02.005.
   PubMed Web of Science ®Google Scholar
• Schwitzer T, Schwan R, Angioi-Duprez K, Ingster-Moati I, Lalanne L, Giersch A, Laprevote V. The cannabinoid system and visual processing: are view on experimental findings and clinical presumptions. Eur Neuropsychopharmacol. 2015;25:100–112. doi:10.1016/j.euroneuro.2014.11.002.
   PubMed Web of Science ®Google Scholar
• Ellison-Wright Z, Sessa B. A persisting perception disorder after cannabis use. Prog Neurol Psychiatr. 2015;9:10–13.
   Google Scholar
• Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The “Endless Trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatr. 2017;8:240.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialog Clin Neurosci. 2001;3:265–279.
   PubMedGoogle Scholar
• Schifano F, Leoni M, Martinotti G, Rawaf S, Rovetto F. Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. Cyberpsychol Behav. 2003;6:405–410. doi:10.1089/109493103322278790.
   PubMedGoogle Scholar
• Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li JH, et al. Following “the Roots” of Kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries. BioMed Res Int. 2015;2015:1.11 doi:10.55/2015/968786.
   Web of Science ®Google Scholar
• World Health Organization. International statistical classification of diseases and related health problems (10th Revision). https://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf (Accessed 02 Oct. 2019.)
   Google Scholar
• World Health Organization. ICD-11 for mortality and morbidity statistics (ICD-11 MMS) 2018 version. https://icd.who.int/browse11/l-m/en (date of the appeal: 14 May 2019). (Accessed 02 Oct. 2019.)
   Google Scholar
• Lerner AG, Gelkopf M, Skladman I, Oyffe I, Finkel B, Sigal M, Weizman A. Flashback and hallucinogen persisting perception disorder: clinical aspects and pharmacological treatment approach. Israel J Psychiatr Relat Sci. 2002;39:92–99.
   PubMed Web of Science ®Google Scholar
• Lerner AG. Flashbacks and HPPD (hallucinogenic persisting perception disorder): clinical aspects and pharmacological treatment; Proceedings of the First World Congress of the World Association on Dual Disorders; 23–26 March 2017; Madrid, Spain.
   Google Scholar
• Lerner AG, Gelkopf M, Skladman I, Rudinski D, Nachshon H, Bleich A. Clonazepam treatment of LSD-induced hallucination persisting perception disorder with anxiety features. Int Clin Psychopharmacol. 2003;18:101–105. doi:10.1097/00004850-200303000-00007.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Shufman E, Kodesh A, Kretzmer G, Sigal M. LSD-induced hallucinogen persisting perception disorder with depressive features treatment with reboxetine. Israel J Psychiatr Relat Sci. 2002;39:100–103.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, Feingold D, Frenkel A, Lerner AG. Clinical characteristics of individuals suffering from schizophrenia and hallucinogen persisting perceptual disorders: a preliminary investigation. J Dual Diagn. 2014;10:79–83. doi:10.1080/15504263.2014.906155.
   PubMed Web of Science ®Google Scholar
• Pettorruso M, De Risio L, Di Nicola M, Martinotti G, Conte G, Janiri L. Allostasis as a conceptual framework linking bipolar disorder and addiction. Front Psychiatry. 2014;5:173. doi:10.3389/fpsyt.2014.00173.
   PubMed Web of Science ®Google Scholar
• Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend. 2011;114:61–67. doi:10.1016/j.drugalcdep.2010.09.006.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, Feingold D, Rudinski D, Katz S, Arturo LG. Schizophrenia and hallucinogen persisting perception disorder: a clinical investigation. Am J Addict. 2015;24:197–199. doi:10.1111/ajad.12204.
   PubMed Web of Science ®Google Scholar
• Lauterbach EC, Abdelhamid A, Annandale JB. Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade. Pharmacopsychiatry. 2000;33:38–41. doi:10.1055/s-2000-8452.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A. LSD-induced hallucinogen persisting perception disorder (HPPD) treatment with clonidine: an open pilot study. Int Clin Psychopharmacol. 2000;18:35–37. doi:10.1097/00004850-200015010-00005.
   Google Scholar
• Kemph JP, DeVane L, Levin GM, Jarecke R, Miller R. Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatr. 1993;32:577–581. doi:10.1097/00004583-199305000-00013.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Oyffe I, Isaacs G, Sigal M. Naltrexone treatment of hallucinogen persisting perception disorder. Am J Psychiatr. 1997;154(3):437.
   Web of Science ®Google Scholar
• Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, Gardini S, Delsignore R. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat. 2001;21:11–17. doi:10.1016/S0740-5472(01)00178-7.
   PubMed Web of Science ®Google Scholar
• Keaney F, Stran J, Gossop M, Marshall EJ, Farrell M, Welch S, Hahn B, Gonzalez A. A double-blind randomized placebo-controlled trial of lofexidine in alcohol withdrawal: Lofexidine is not a useful adjunct to chlordiazepoxide. Alcohol Alcohol. 2001;36:426–430. doi:10.1093/alcalc/36.5.426.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Goodman C, Rudinski D, Lev-Ran S. LSD flashbacks – the appearance of new visual imagery not experienced during initial intoxication: two case reports. Israel J Psychiatr Relat Sci. 2014;51:307–309.
   PubMed Web of Science ®Google Scholar
• Coppola M, Mondola R. JWH-122 consumption adverse effects: a case of hallucinogen persisting perception disorder five-year follow-up. J Psychoact Drugs. 2017;49:262–265. doi:10.1080/02791072.2017.1316431.
   PubMed Web of Science ®Google Scholar
• Moskowitz D. Use of haloperidol to reduce LSD flashbacks. Milit Med. 1971;136:754–756. doi:10.1093/milmed/136.9.754.
   PubMed Web of Science ®Google Scholar
• Anderson WH, O'Malley JE. Trifluoperazine for the ‘trailing’ phenomenon. JAMA. 1972;220:1244–1245. doi:10.1001/jama.1972.03200090066017.
   PubMed Web of Science ®Google Scholar
• Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 1996;14:285–298. doi:10.1016/0893-133X(95)00136-2.
   PubMed Web of Science ®Google Scholar
• Thurlow HJ, Girvin JP. Use of antiepileptic medication in treating flashbacks from hallucinogenic drugs. Can Med Assoc J. 1971;105:947–948.
   PubMed Web of Science ®Google Scholar
• Aicardi J. Epilepsy: a comprehensive textbook, 2nd ed. Philadelphia, PA: Wolters Kluwer Health/LippincottWilliams & Wilkins, 2008.
   Google Scholar
• Gaillard MC, Borruat FX. Persisting visual hallucinations and illusions in previously drug-addicted patients. Klin Monatsbl Augenheilkd. 2003;220:176–178. doi:10.1055/s-2003-38173.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Romanelli R, Andreoli S, Pozzi G, Moroni N, Janiri L. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol Clin Exp. 2007;22:149–156. doi:10.1002/hup.833.
   PubMed Web of Science ®Google Scholar
• Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Exp Opin Investig Drugs. 2012;21:1243–1245. doi:10.1517/13543784.2012.703179.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, De Vita O, Hatzigiakoumis DS, Guglielmo R, Santucci B, Aliotta F, Romanelli R, Verrastro V, Petruccelli F, et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34:709–715. doi:10.1097/JCP.0000000000000228.
   PubMed Web of Science ®Google Scholar
• Casa B, Bosio A. Levetiracetam efficacy in hallucinogen persisting perception disorders: a prospective study. J Neurol Sci. 2005;238:S504.
   Web of Science ®Google Scholar
• Markel H, Lee A, Holmes RD, Domino EF. LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr. 1994;125:817–819. doi:10.1016/S0022-3476(06)80189-7.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Skladman I, Kodesh A, Sigal M, Shufman E. LSD-induced hallucinogen persisting perception disorder treated with clonazepam: two case reports. Israel J Psychiatr Relat Sci. 2001;38:133–136.
   PubMed Web of Science ®Google Scholar
• Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131–181. doi:10.1016/j.pharmthera.2003.11.002.
   PubMed Web of Science ®Google Scholar
• Passie T, Halpern JH, American Society of Addiction Medicine. The pharmacology of hallucinogens. In: Ries R, Miller SC, Saitz R, Fiellin DA, editors. The ASAM principles of addiction medicine. 5th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
   Google Scholar
• Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Top Behav Neurosci. 2018;36:333–360. doi:10.1007/7854_2016_457.
   PubMedGoogle Scholar
• Holland D, Passie T. Flashback-Phänomeneals Nachwirkung von Halluzinogeneinnahme: Eine kritische Untersuchung zu klinischen und ätiologischen Aspekten (Bewusstsein-Kognition-Erleben). Berlin: VWB, Verlag für Wissenschaft und Bildung; 2011.
   Google Scholar
• Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacology. 1998;19:241–251. doi:10.1016/S0893-133X(98)00013-X.
   PubMed Web of Science ®Google Scholar
• Winter JC. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl). 2009;203:251–263. doi:10.1007/s00213-008-1356-8.
   PubMed Web of Science ®Google Scholar
• Brunt TM, Koeter MW, Niesink RJ, van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl). 2012;220:751–762. doi:10.1007/s00213-011-2529-4.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22(5):513–21. doi:10.1016/S0893-133X(99)00148-7.
   PubMed Web of Science ®Google Scholar
• Peiro AM, Farre M, Roset PN, Carbo M, Pujadas M, Torrens M, Cami J, de la Torre R. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart. Eur Neuropsychopharmacol. 2015;25:1637–1649. doi:10.1016/j.euroneuro.2015.05.007.
   PubMed Web of Science ®Google Scholar
• Passie T, Schneider U, Emrich HM. Persisting continuous visual perception disorder in a chronic MDMA (“ecstasy”) user. Aust NZ J Psychiatr. 2002;36:266–267.
   PubMed Web of Science ®Google Scholar
• Hanck L, Schellekens AF. Persisterende waarnemingsstoornissen na het gebruik van ecstasy. [Hallucinogen persisting perception disorder after ecstasy use]. Ned Tijdschr Geneeskd. 2013:157–124. [Article in Dutch]
   Google Scholar
• Kurtom M, Henning A, Espiridion ED. Hallucinogen-persisting perception disorder in a 21-year-old man. Cureus. 2019;11:e4077. doi:10.7759/cureus.4077.
   PubMed Web of Science ®Google Scholar
• Anderson L, Lake H, Walterfang M. The trip of a lifetime: hallucinogen persisting perceptual disorder. Australas Psychiatr. 2018;26:11–12. doi:10.1177/1039856217726694.
   PubMed Web of Science ®Google Scholar
• Brodrick J, Mitchell BG. Hallucinogen persisting perception disorder and risk of suicide. J Pharm Pract. 2016;29:431–434. doi:10.1177/0897190014566314.
   PubMedGoogle Scholar